Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells

British Journal of Cancer

Volumn 95, Issue 9, 2006, Pages 1220-1228

  Byron, S A ^a   Horwitz, K B ^b   Richer, J K ^b   Lange, C A ^a   Zhang, X ^a   Yee, D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Insulin receptor substrate; Insulin like growth factor I; Motility; Proliferation; Type I insulin like growth factor receptor

Indexed keywords

BIOLOGICAL MARKER; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; SMALL INTERFERING RNA; SOMATOMEDIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHOPROTEINS; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 33750453743     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603354     Document Type: Article

References (50)

1. Albrecht-Buehler G (1977) The phagokinetic tracks of 3T3 cells. Cell 11: 395-404
2. Arteaga CL (1992) Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 22: 101-106
3. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull Jr FC, Allred DC, Osborne CK (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418-1423
4. Arteaga CL, Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49: 6237-6241
5. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23: 5323-5333
6. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921
7. Byron SA, Yee D (2003) Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Semin Oncol 30: 125-132
8. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE (2003) Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem 278: 25323-25330
9. Cui X, Lazard Z, Zhang P, Hopp TA, Lee AV (2003) Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 22: 6937-6941
10. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D (1993) Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157: 229-236
11. Garber K (2005) IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst 97: 790-792
12. Horwitz KB, Mockus MB, Lessey BA (1982) Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 28: 633-642
13. Ibrahim YH, Yee D (2005) Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res 11: 944s-950s
14. Jackson JG, White MF, Yee D (1998) Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 273: 9994-10003
15. Jackson JG, Yee D (1999) IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. Growth Horm IGF Res 9: 280-289
16. Jackson JG, Zhang X, Yoneda T, Yee D (2001) Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20: 7318-7325
17. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9: 1603-1614
18. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ (1979) Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15: 659-670
19. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193
20. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE (1997a) A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 272: 21403-21407
21. Lavan BE, Lane WS, Lienhard GE (1997b) The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272: 11439-11443
22. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13: 787-796
23. Meyer GE, Shelden E, Kim B, Feldman EL (2001) Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene 20: 7542-7550
24. Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM (2004) Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 24: 9726-9735
25. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV (2001) Re-expression of estrogen receptor alpha in estrogen receptor alpha- negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 61: 5771-5777
26. Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G (2005) Targeted therapy: wave of the future. J Clin Oncol 23: 1776-1781
27. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R (2001) Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 20: 490-500
28. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277: 5209-5218
29. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, Yee D (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3: 103-109
30. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279: 5017-5024
31. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63: 627-635
32. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8: 197-209
33. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54: 3868-3877
34. Sepp-Lorenzino L, Rosen N, Lebwohl DE (1994) Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. Cell Growth Differ 5: 1077-1083
35. Shaw LM (2001) Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 21: 5082-5093
36. Sun XJ, Pons S, Wang LM, Zhang Y, Yenush L, Burks D, Myers Jr MG, Glasheen E, Copeland NG, Jenkins NA, Pierce JH, White MF (1997) The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol Endocrinol 11: 251-262
37. Surmacz E (2000) Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5: 95-105
38. Sutherland RL, Lee CS, Feldman RS, Musgrove EA (1992) Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists. J Steroid Biochem Mol Biol 41: 315-321
39. Tobe K, Tamemoto H, Yamauchi T, Aizawa S, Yazaki Y, Kadowaki T (1995) Identification of a 190-kDa protein as a novel substrate for the insulin receptor kinase functionally similar to insulin receptor substrate-1. J Biol Chem 270: 5698-5701
40. Twentyman PR, Luscombe M (1987) A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285
41. Valentinis B, Navarro M, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K, Baserga R (2000) Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 275: 25451-25459
42. Vassen L, Wegrzyn W, Klein-Hitpass L (1999) Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol Endocrinol 13: 485-494
43. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A (2005) A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165-172
44. Wang LM, Myers Jr MG, Sun XJ, Aaronson SA, White M, Pierce JH (1993) IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 261: 1591-1594
45. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP (1994) The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14: 8356-8364
46. White MF, Maron R, Kahn CR (1985) Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185 000 protein in intact cells. Nature 318: 183-186
47. Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D, Yee D (2004) Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 83: 161-170
48. Zhang X, Lin M, van Golen KL, Yoshioka K, Itoh K, Yee D (2005) Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Res Treat 93: 159-168
49. Zhang X, Yee D (2000) Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2: 170-175
50. Zhang X, Yee D (2002) Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 62: 4369-4375